Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for oncology and autoimmune and inflammatory diseases. News commonly centers on bexobrutideg (NX-5948), a Bruton’s tyrosine kinase degrader, including clinical data in chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, as well as updates tied to the DAYBreak development program.
Company updates also cover Nurix’s DEL-AI discovery platform, preclinical degrader programs against targets such as pan-mutant BRAF, CBL-B and Aurora kinase A, and partnered inflammation and immunology programs involving IRAK4 and STAT6 degraders. Recurring announcements include financial results, corporate presentations, scientific meeting data, pipeline progress, capital actions and board or governance changes.
Nurix Therapeutics (Nasdaq: NRIX) reported a $10 million development milestone payment triggered by collaborator Sanofi initiating a Phase 1 first-in-human trial of SAR448272/NX-3911, an oral STAT6 degrader for type 2 inflammatory diseases such as atopic dermatitis and asthma.
Including this payment, Nurix has earned approximately $139 million under the 2019 collaboration and remains eligible for about $453 million in additional STAT6 program milestones, plus potential royalties. Sanofi is solely responsible for clinical development, while Nurix retains a U.S. co-development and co-promotion option.
Nurix Therapeutics (Nasdaq: NRIX) reported enrollment of the first patient in the global registrational Phase 3 DAYBreak CLL-306 trial (NCT07516093) of bexobrutideg in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor. The randomized study, conducted under Nurix’s collaboration with Roche, is the first Phase 3 trial for bexobrutideg.
The trial will enroll about 620 patients, randomized 1:1 to receive bexobrutideg 600 mg orally once daily or pirtobrutinib, the current standard of care in this setting. Dual primary endpoints are objective response rate and progression-free survival by independent review, and the study is designed to evaluate potential superiority of bexobrutideg and support global regulatory submissions.
Nurix Therapeutics (Nasdaq: NRIX) reported the closing of its previously announced global collaboration with Roche to co-develop and co-commercialize the BTK degrader bexobrutideg, enabled by expiration of the Hart-Scott-Rodino waiting period. The deal covers malignant hematology, immunology and neurology indications.
Nurix will receive an upfront cash payment of $700 million and is eligible for up to $2.3 billion in potential development, regulatory and sales milestones. Development costs will be shared, with 40% funded by Nurix and 60% by Roche. In the United States, the companies will co-commercialize bexobrutideg and will equally split profits and losses from commercialization across all indications.
Outside the U.S., Roche will lead commercialization, while Nurix will receive tiered royalties in the low- to high-teens. The partners plan a broad clinical development program, including ongoing and planned studies in chronic lymphocytic leukemia (CLL), other B-cell malignancies, multiple sclerosis (MS) and chronic spontaneous urticaria (CSU).
Nurix Therapeutics (Nasdaq: NRIX) reported fiscal Q2 2026 results and a major global collaboration with Roche for BTK degrader bexobrutideg, worth up to $2.3 billion including a $700 million upfront payment.
Q2 revenue was $9.0 million, net loss $89.5 million, and cash was $443.5 million, with pro-forma cash of about $1.14 billion including the expected Roche upfront.
Nurix Therapeutics (Nasdaq: NRIX) reported updated Phase 1a/b data for BTK degrader bexobrutideg (NX-5948) in relapsed/refractory and earlier-line CLL/SLL. Results showed an 83% ORR and median PFS of 22.1 months in heavily pretreated patients, high ORR in earlier-line cohorts, and a generally well-tolerated safety profile with 5.6% discontinuations from adverse events.
Nurix Therapeutics (Nasdaq: NRIX) announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg (NX-5948), an oral BTK degrader, across malignant hematology, immunology and neurology.
Nurix receives $700 million upfront, is eligible for milestones up to $2.3 billion, will share U.S. profits 50/50, and earn ex-U.S. royalties.
Nurix Therapeutics (Nasdaq: NRIX) reported new preclinical and Phase 1 translational data for its oral BTK degrader bexobrutideg (NX-5948) in chronic spontaneous urticaria (CSU). Data show potent, highly selective BTK degradation across key immune cells and rapid, robust BTK loss in blood and skin of healthy volunteers.
According to Nurix, bexobrutideg achieved ~25-fold greater potency than remibrutinib in preclinical FcεRI-driven models and produced larger reductions in ear swelling and vascular permeability in a mouse anaphylaxis model, supporting further clinical development in CSU and broader inflammation and immunology indications.
Nurix Therapeutics (Nasdaq: NRIX) announced that president and CEO Arthur T. Sands will join fireside chats at two upcoming investor conferences.
He is scheduled for the RBC Global Healthcare Conference on May 20, 2026 at 1:30 p.m. ET and the Jefferies Global Healthcare Conference on June 3, 2026 at 11:05 a.m. ET. Live and archived webcasts will be accessible for 30 days in the Investors section of Nurix's website.
Nurix Therapeutics (Nasdaq: NRIX) announced that updated efficacy and safety data from its ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in chronic lymphocytic leukemia (CLL) will be presented in an oral session at the 31st European Hematology Association Congress (EHA2026) in Stockholm, Sweden, on June 14, 2026.
Nurix Therapeutics (Nasdaq: NRIX) disclosed preclinical and early clinical data at AACR 2026 across three oncology programs: pan-mutant BRAF (NRX-0305), CBL-B (NX-1607), and AURKA (NRX-4972).
Key findings include a 142% lifespan increase for NRX-0305 in a BRAF inhibitor–resistant brain metastasis PDX, activity across 14 BRAF PDX models, sub-nanomolar CBL-B inhibitor binding with pharmacodynamic biomarker modulation in patients, and superior SCLC survival with NRX-4972 versus AURKA inhibitors.